Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
- 1 October 2014
- journal article
- clinical trial
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (10) , 923-927
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATIONJournal of Hepatology, 2014
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experienceJournal of Hepatology, 2014
- Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis CAmerican Journal of Transplantation, 2013
- Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatmentJournal of Hepatology, 2013
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialThe Lancet Infectious Diseases, 2012
- Post–liver transplant cholestatic hepatitis C: A systematic review of clinical and pathological findings and application of consensus criteriaLiver Transplantation, 2010
- The natural history of recurrent hepatitis C and what influences thisLiver Transplantation, 2008
- Evolution of liver transplantation in Europe: Report of the European Liver Transplant RegistryLiver Transplantation, 2003
- The burden of hepatitis C in the United StatesHepatology, 2002